Airway Clearance Devices
Customize your policy alerts
Sign up for univerahealthcare Policy 1.01.15 alerts
Get alerted when Policy 1.01.15 changes without checking for updates manually.
Monitor payer policy activity
Covers medical necessity and coverage criteria for airway clearance devices (HFCC, IPV, MI‑E) including repair and replacement rules, documentation and prior authorization expectations for Univera Healthcare members.
Revised conservative treatment requirements from 'and' to an 'or' statement for a positive policy intent change.
Separated criteria for high frequency chest wall compression and intrapulmonary percussive ventilation devices into two distinct policy statements.
Added CPT code E0469.
Removed criteria that is not [text truncated in source].
Coverage Criteria for Airway Clearance Devices
High-Frequency Chest Wall Compression Devices (HFCC)
Covered when ALL of the following are met:
Examples of HFCC devices: Monarch Airway Clearance System, AffloVest, Smart Vest
Intrapulmonary Percussive Ventilation (IPV) Devices
Covered when ALL of the following are met:
Examples of IPV devices: Percussionaire, Percussinator IPV, TXP, Impulsator
Other applications of IPV (including adjunct to chest physical therapy or use in COPD) are considered investigational.
Mechanical Insufflation-Exsufflation (MI-E) Devices
Covered when ALL of the following are met:
Mechanical insufflation-exsufflation = cough-assist devices
DME Repair — medical necessity
Repair of medically necessary airway clearance devices or components not under warranty is considered medically appropriate when ALL of the following are met:
Documentation requirement for repair
DME Replacement — medical necessity
Replacement of medically necessary airway clearance devices or components not under warranty is considered medically appropriate when EITHER of the following are met:
Replacement — Not Medically Necessary
Device-specific coverage considerations
Coverage considerations based on device class and patient population
References: systematic reviews and COPD trials
See Veldhoen et al 2023; guideline support from AAN and ACCP
Evidence limited and inconsistent
Policy-level statement: insufficient evidence
Policy conclusion and guideline-supported uses
Policy stance and guideline context
Policy-level conclusion
CHEST 2018 consensus-based suggestions
ACCP 2023 conditional recommendations
AAN 2009 (reaffirmed 2023)
Cystic Fibrosis Foundation guidelines
Revised coverage criteria notes
Policy edits and separation of device-specific criteria (as noted in revision history).
See committee summary of changes
See summary of changes
See summary of changes
Use of HFCC (high-frequency chest wall compression) or IPV (intrapulmonary percussive ventilation) devices as an adjunct to chest physical therapy or for treatment of other lung diseases such as COPD is considered investigational and is not supported as a covered indication.
Equipment that is damaged or lost as a result of patient neglect, theft, or abuse, or equipment for which another available coverage source (for example, homeowners, rental, auto, or liability insurance) exists, is ineligible for coverage.
The policy excludes or does not support the routine use of Oscillation and Lung Expansion (OLE) therapy when the request is based on demonstrating an improvement in net health outcome because the evidence is insufficient to show benefit.
No additional explicit exclusions are listed in the provided extract beyond those already stated for investigational uses and noncovered replacement/repair circumstances.
If a product does not cover a service under its benefit design, the medical policy criteria do not apply; coverage is operationally excluded when the product benefit excludes the service.
Applications beyond the specified, device‑class indications — including use as an adjunct to chest physical therapy or for general COPD treatment — are considered investigational and therefore not covered under this policy.
Replacement of a properly functioning device, component, or accessory for reasons such as acquisition of advanced technology or for aesthetic preference is considered not medically necessary and is not covered.
For Oscillation and Lung Expansion (OLE) therapy the policy concludes the available evidence is insufficient to determine an improvement in net health outcome, supporting a position that routine coverage is not established.
The policy states that evidence is insufficient to determine an improvement in net health outcome for certain therapies; specific additional not medically necessary conditions are not detailed in the provided extract.
The summary of changes notes that some criteria were removed (text truncated in the extract); the detailed removed not medically necessary statements are not present in the provided chunks.
Coding and Billing References
| No codes listed |
| A7025 | High frequency chest wall oscillation system vest, replacement for use with patient owned equipment, each. |
| A7026 | High frequency chest wall oscillation system hose, replacement for use with patient owned equipment, each. |
| E0469 | Lung expansion airway clearance, continuous high frequency oscillation, and nebulization device. |
| E0481 | Intrapulmonary percussive ventilation system and related accessories. |
| E0482 | Cough stimulating device, alternating positive and negative airway pressure. |
| E0483 | High frequency chest wall oscillation system, includes all accessories and supplies, each |
| No codes listed |
| E0469 | Device code added (as listed in policy text) |
Provider Actions, Prior Authorization, and Documentation
Prior authorization required to document medical appropriateness
Prior authorization is required to establish medical appropriateness by demonstrating the listed diagnostic and treatment-failure criteria for the specific airway clearance device class.
Authorization and coverage are contract dependent
Prior authorization and coverage for an airway clearance device are contract dependent unless mandated by federal or state law; verify product coverage before submitting requests.
Pulmonologist must generate referral
Referral for an airway clearance device must be generated by a pulmonologist per policy guidelines.
PA expected for MI-E and related devices in impaired-cough populations
Prior authorization is expected for device coverage when used for individuals with impaired cough due to neuromuscular disorders, spinal cord injury, or similar conditions where respiratory muscle weakness compromises secretion clearance.
PA and coding follow policy and CMS LCDs
Prior authorization requirements follow this medical policy and applicable product coverage; CMS Local Coverage Determinations for HFCC, IPV, and mechanical in-exsufflation are cited as reference.
- See CMS LCDs: L33785 (HFCC), L33786 (IPV), L33795 (MI-E)
Require documented failure/contraindication or lack of resources for standard therapies
Documented failure of, contraindication to, or lack of available resources to administer standard treatments (e.g., pharmacotherapy, postural drainage, daily chest percussion, Flutter or Acapella) is required before advanced device approval.
- Acceptable demonstration: failure, contraindication, or unavailable resources for standard treatments
Replacement allowed when nonrepairable, cost-prohibitive, or clinically required
Replacement is appropriate when the DME is nonrepairable or the cost of repair exceeds replacement cost, or when a documented change in the patient's condition makes the present unit non-functional and replacement is expected to improve function.
- Replacement criteria include nonrepairable device or repair cost > replacement cost
- Replacement may be appropriate for change in patient condition making current unit non-functional
Consider simpler self-administered ACTs before device escalation
Consider less complex or self-administered airway clearance techniques (e.g., PEP, autogenic drainage, active cycle breathing) before escalating to device-based therapy when feasible.
- Examples: autogenic drainage, active cycle breathing techniques, PEP devices
- Evidence suggests many trials show equivalence to more complex devices
No mandated step-therapy order — individualize treatment
No explicit step-therapy sequence is specified; guidelines recommend individualized airway clearance therapies and considering adjunctive or alternative techniques for neuromuscular disease.
Conservative treatment requirement changed to 'or'
The conservative treatment requirement was revised from an 'and' to an 'or' statement; meeting one of the conservative treatments may satisfy the policy intent.
Document date of DME initiation and warranty for repair requests
Physician documentation for DME repair must include the date of DME initiation and manufacturer warranty information, if applicable.
- Include date of DME initiation
- Provide manufacturer warranty status/details if applicable
Required physician documentation for repair requests
Physician documentation must include the date of DME initiation; manufacturer warranty information if applicable; and an attestation that the patient has been compliant with use of the DME and will continue to benefit from its use.
- Attestation of patient compliance and continued benefit is required
Document diagnosis and rationale for device selection
Documentation should support the clinical indication causing impaired cough or airway clearance (e.g., neuromuscular disorders, spinal cord injury, cystic fibrosis) and provide the clinical rationale for device selection.
- Document diagnosis that impairs secretion clearance and reason device is chosen
Document FDA approval/clearance as appropriate
Airway clearance devices are regulated by the FDA; providers should ensure device FDA approval/clearance is documented as appropriate.
Follow product coverage lines and applicable LCDs
Services are contract dependent; follow product coverage lines (commercial, Medicaid, Medicare) and applicable Medicare LCDs referenced in the policy when determining coverage applicability.
- If a product does not cover a service, medical policy criteria do not apply
Denials likely if diagnostic or conservative-therapy documentation is incomplete
Lack of documentation showing a diagnosis that impairs clearance of secretions, demonstrated need (exacerbations/inability to clear mucus), or failure/contraindication to conservative therapy may lead to denial.
- Ensure documentation of diagnosis impairing secretion clearance
- Document demonstrated need (exacerbations/inability to clear secretions)
- Document failure, contraindication, or unavailability of conservative treatments
Do not bill for repair/replacement when damage is due to neglect/theft or another payer is available
Repairs or replacements for equipment damaged due to patient neglect, theft, or abuse, or when another coverage source (e.g., homeowners, renters insurance) is available, are not covered.
OLE therapy lacks sufficient evidence — denial risk
Oscillation and Lung Expansion (OLE) therapy is stated to have insufficient evidence to determine improvement in net health outcome; requests based on demonstrated improvement in net health outcome may be denied.
Evidence insufficiency may trigger claim denial
Claims may be denied when the requested technology does not have sufficient evidence of improvement in net health outcome.
Coverage depends on contract and applicable LCDs
Coverage may be governed by contract and CMS local coverage determinations; if a product does not cover a service, the policy criteria do not apply.
Background and Definitions
Airway clearance devices are used to assist patients who cannot effectively clear respiratory secretions due to underlying disorders such as cystic fibrosis, neuromuscular disease, high spinal cord injury, or diffuse bronchiectasis; these devices support bronchial hygiene when patients are unable to clear secretions by conventional means.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.